Zurich, Switzerland: +41 - 43 434 80 33   |   US: (510) 962-8903   |   support@traininng.com

Graeme Ladds

CEO, PharSafer Associates Ltd

Dr. Graeme Ladds has been involved in Drug Safety for the last 30 years. Graeme has been working as Head of Global Pharmacovigilance and EU QP PV for many large (and small) Pharma, and has been CEO for the last 15 years for PharSafer. His previous role in industry was Head of Global Drug Safety at Shire Pharmaceuticals.

Fifteen years ago, Graeme set up his own consulting Company PharSafer Associates Ltd, a niche CRO providing both Clinical and post marketing drug safety and medical information services to the Pharma industry globally, from total outsourcing of Safety and Medical Services to bespoke projects and interim requirements. Based in the UK, the Company performs full safety services for companies from the USA, Canada, India, Europe and Japan and has been inspected on site by the Regulators and clients. PharSafer employs science graduates, pharmacists, physicians all with varied and extensive pharmacovigilance experience.



No Live Webinars found.




No Recorded Webinars found.
300005sem
Graeme Ladds
Date: 01 & 02 October, 2018   |   Time: 09:00 AM To 05:00 PM CEST

EU Regulatory Inspections - Format, Audits, Preparation and the Legislation

The delegates will be provided with information concerning a Safety Department they have been asked to audit. The safety department in question is the Company Headquarters Safety Department based in the EU.

Price: ¤999.00

300006sem
Graeme Ladds
Date: 19 & 20 November, 2018   |   Time: 09:00 AM To 05:00 PM CEST

The EU Legislation for Post-Marketing Pharmacovigilance - Current updates.

To ensure Regulatory compliance to the new Pharmacovigilance system introduced in the EU in 2012 and its evolution.

Price: ¤999.00

300004sem
Graeme Ladds
Date: 03 & 05 December, 2018   |   Time: 09:00 AM To 05:00 PM CEST

An Introduction to Global Pharmacovigilance - Principles and Requirements

The course will cover the background to Pharmacovigilance; the global nature of the Pharmacoviglance legislation as well as major topics concerning reporting adverse reactions.

Price: ¤1,299.00